Influenza treatment

Mechanisms of inhibition of virus entry by peptides (viral entry can be blocked via interaction of peptide with hemagglutinin, commonly interacting with residue of sialic acid)[1]
Specialty| Infectious disease

Treatments for influenza include a range of medications and therapies that are used in response to disease influenza. Treatments may either directly target the influenza virus itself; or instead they may just offer relief to symptoms of the disease, while the body's own immune system works to recover from infection.[2]

The main classes of antiviral drugs used against influenza are neuraminidase inhibitors, such as zanamivir and oseltamivir, polymerase acidic endonuclease inhibitors such as baloxavir marboxil, or inhibitors of the viral M2 protein, such as amantadine and rimantadine. These drugs can reduce the severity of symptoms if taken soon after infection and can also be taken to decrease the risk of infection. However, virus strains have emerged that show drug resistance to some classes of drug.[3][4][5]

## Contents

* 1 Symptomatic
* 1.1 Over-the-counter medication
* 2 Antivirals
* 2.1 Interferons
* 2.2 Resistance
* 3 Research
* 3.1 Peptides
* 3.2 Transfused antibodies
* 3.3 Ex vivo culture of T lymphocytes
* 4 Supplements
* 4.1 Elderberry
* 4.2 Green tea
* 5 References
* 6 Further reading
* 7 External links

## Symptomatic[edit | edit source]

Influenza (Flu)

Types

* Avian
* A/H5N1 subtype
* Canine
* Equine
* Swine
* A/H1N1 subtype

Vaccines

* 2009 pandemic
* Pandemrix
* Live attenuated
* Seasonal flu vaccine brands

Treatment

* Amantadine
* Laninamivir
* Oseltamivir
* Peramivir
* Rimantadine
* Umifenovir
* Vitamin D
* Zanamivir

Pandemics

* 1918 Spanish flu
* 1957 Asian flu
* 1968–1969 Hong Kong flu
* 2009 swine flu

Outbreaks

* 1976 swine flu
* 2006 H5N1 India
* 2007 Australian equine
* 2007 Bernard Matthews H5N1
* 2008 West Bengal
* 2015 United States H5N2 outbreak

See also

* Flu season
* Influenza evolution
* Influenza research
* Influenza-like illness
* Vaccine reformulations

* v
* t
* e

The US Centers for Disease Control and Prevention (CDC), recommends that people with influenza:[6][7]

* Stay at home
* Get plenty of rest
* Drink a lot of liquids
* Do not smoke or drink alcohol
* Consider over-the-counter medications for symptoms
* Consult a physician early on
* Watch for emergency warning signs

Warning signs indicate that the disease is becoming serious and needs immediate medical attention. These include:[8][9]

* Difficulty breathing or shortness of breath
* Pain or pressure in the chest or abdomen
* Dizziness
* Confusion
* Severe or persistent vomiting

In children other warning signs include irritability, failing to wake up and interact, rapid breathing, and a blueish skin color. Another warning sign in children is if the flu symptoms appear to resolve, but then reappear with fever and a bad cough.[6]

### Over-the-counter medication[edit | edit source]

Antiviral drugs are prescription-only medication in the United States. Readily available over-the-counter medications do not directly affect the disease, but they do provide relief from influenza symptoms, as illustrated in the table below:

OTC medicines provide relief for flu symptoms[10] Symptom(s)  | OTC Medicine

|

fever, aches, pains, sinus pressure, sore throat | analgesics
nasal congestion, sinus pressure  | decongestants
sinus pressure, runny nose, watery eyes, cough  | antihistamines
cough  | cough suppressant
sore throat | local anesthetics

Children and teenagers with flu symptoms (particularly fever) should avoid taking aspirin as taking aspirin in the presence of influenza infection (especially Influenzavirus B) can lead to Reye syndrome, a rare but potentially fatal disease of the brain.[11]

## Antivirals[edit | edit source]

Antiviral drugs directly target the viruses responsible for influenza infections. Generally, anti-viral drugs work optimally when taken within a few days of the onset of symptoms.[12] Certain drugs are used prophylactically, that is they are used in uninfected individuals to guard against infection.[13]

Four licensed influenza antiviral agents are available in the United States: zanamivir, oseltamivir phosphate, peramivir, and baloxavir marboxil.[14] They are available through prescription only.[14]

Antivirals to treat influenza[14] Class | Effective against | Drug name (INN) | Brand name | Year approved | Manufacturer

|
|
|
|
|

Neuraminidase inhibitors | Influenza A & B  | zanamivir | Relenza  | 1999  | GlaxoSmithKline
oseltamivir | Tamiflu  | 1999  | Hoffmann-La Roche
peramivir | Rapivab  | 2014  | BioCryst Pharmaceuticals
Cap-dependent endonuclease inhibitor  | Influenza A & B  | baloxavir marboxil | Xofluza  | 2018  | Shionogi Pharma Co., Ltd.

In Russia and China a drug called arbidol is also used as a treatment. Testing of the drug has predominantly occurred in these countries and, although no clinical trials have been published demonstrating this is an effective drug, some data suggest that this could be a useful treatment for influenza.[15][16]

### Interferons[edit | edit source]

The molecular structure of human interferon-alpha

Interferons are cellular signalling factors produced in response to viral infection. Research into the use of interferons to combat influenza began in the 1960s in the Soviet Union, culminating in a trial of 14,000 subjects at the height of the Hong Kong Flu of 1969, in which those treated prophylactically with interferon were more than 50% less likely to suffer symptoms, though evidence of latent infection was present.[17] In these early studies leukocytes were collected from donated blood and exposed to a high dose of Newcastle disease, causing them to release interferons. Although interferon therapies became widespread in the Soviet Union, the method was doubted in the United States after high doses of interferon proved ineffective in trials. Though the 1969 study used 256 units of interferon, subsequent studies used up to 8.4 million units. It has since been proposed that activity of interferon is highest at low concentrations.[18] Phase III trials in Australia are planned for 2010, and initial trials are planned in the U.S. for late 2009.[19]

Interferons have also been investigated as adjuvants to enhance to effectiveness of influenza vaccines. This work was based on experiments in mice that suggested that type I interferons could enhance the effectiveness of influenza vaccines in mice.[20] However, a clinical trial in 2008 found that oral dosing of elderly patients with interferon-alpha actually reduced their immune response to an influenza vaccine.[21]

Viferon is a suppository of (non-pegylated[22]) interferon alpha-2b, ascorbic acid (vitamin C), and tocopherol (vitamin E) which was reported in two small studies to be as effective as arbidol.[23][24] Another interferon alfa-2b medicine, "Grippferon", nasal drops, is used for treatment and emergency prevention of Influenza and cold.[25] Its manufacturers have appealed to the WHO to consider its use against avian influenza and H1N1 Influenza 09 (Human Swine Flu), stating that it was used successfully in Russia for eight years, but that "the medical profession in Europe and the USA is not informed about this medicine".[26]

### Resistance[edit | edit source]

Influenza viruses can show resistance to anti-viral drugs. Like the development of bacterial antibiotic resistance, this can result from over-use of these drugs. For example, a study published in the June 2009 Issue of Nature Biotechnology emphasized the urgent need for augmentation of oseltamivir (Tamiflu) stockpiles with additional antiviral drugs including zanamivir (Relenza) based on an evaluation of the performance of these drugs in the scenario that the 2009 H1N1 'Swine Flu' neuraminidase (NA) were to acquire the tamiflu-resistance (His274Tyr) mutation which is currently widespread in seasonal H1N1 strains.[27] Yet another example is in the case of the amantadines treatment may lead to the rapid production of resistant viruses, and over-use of these drugs has probably contributed to the spread of resistance.[28] In particular, this high-level of resistance may be due to the easy availability of amantadines as part of over-the-counter cold remedies in countries such as China and Russia,[29] and their use to prevent outbreaks of influenza in farmed poultry.[30][31]

On the other hand, a few strains resistant to neuraminidase inhibitors have emerged and circulated in the absence of much use of the drugs involved, and the frequency with which drug resistant strains appears shows little correlation with the level of use of these drugs.[32] However, laboratory studies have shown that it is possible for the use of sub-optimal doses of these drugs as a prophylactic measure might contribute to the development of drug resistance.[32]

During the United States 2005–2006 influenza season, increasing incidence of drug resistance by strain H3N2 to amantadine and rimantadine led the CDC to recommend oseltamivir as a prophylactic drug, and the use of either oseltamivir or zanamivir as treatment.[33][34]

## Research[edit | edit source]

Several generic prescription medications might prove useful to treat a potential H5N1 avian flu outbreak, including statins, fibrates, and chloroquine.[35][36][37]

### Peptides[edit | edit source]

a)Most common interactions between antiviral peptides with an influenza virus lipid bilayer b)image shows polymerase assembly in virus replication cycle; antiviral peptides may bind to PB2 subunit and prevent the assembly of influenza polymerase complex[1]

Peptides are composed of an amino acid chain, with a M.W. between 400 and 5000 Da . More than a century ago, insulin was created as the first peptide drug to manage diabetes. With newly available synthetic technologies an increase in the development of peptides has occurred[38][39]

Viral RNA-dependent RNA polymerase is made-up of 3 polymerase subunits which are PB1, PB2 and PA, each in turn has its own function or respondsibility. In the end, Viral RNA-dependent RNA polymerase is bond together via noncovalent interactions, a disruption of RdRp in the interaction between PB1 and PA/PB2 is a logical target for a anti-influenza drug, because such a disruption would stop the enzyme task and hence viral replication[1]

### Transfused antibodies[edit | edit source]

An alternative to vaccination used in the 1918 flu pandemic was the direct transfusion of blood, plasma, or serum from recovered patients. Though medical experiments of the era lacked some procedural refinements, eight publications from 1918 to 1925 reported that the treatment could approximately halve the mortality in hospitalized severe cases with an average case-fatality rate of 37% when untreated.[40][41]

Bovine colostrum might also serve as a source of antibodies for some applications.[42]

### Ex vivo culture of T lymphocytes[edit | edit source]

Human T lymphocytes can be expanded in vitro using beads holding specific antigens to activate the cells and stimulate growth. Clonal populations of CD8+ cytotoxic T cells have been grown which carry T cell receptors specific to influenza. These work much like antibodies but are permanently bound to these cells. (See cellular immunity). High concentrations of N-acetylcysteine have been used to enhance growth of these cells. This method is still in early research.[43][44]

## Supplements[edit | edit source]

Malnutrition can reduce the ability of the body to resist infections and is a common cause of immunodeficiency in the developing world.[45] Seasonal variation in sunlight exposure, which is required for vitamin D synthesis within the body, has been proposed as one of the factors accounting for the seasonality of influenza.[46] A meta-analysis indicated some support for adjunctive vitamin D therapy for influenza, but called for more rigorous clinical trials to settle the issue conclusively.[47]

A review of alternative medicines in influenza treatment details evidence suggesting that N-acetylcysteine, elderberry, or a combination of Eleutherococcus senticosus and Andrographis paniculata may help to shorten the course of influenza infection.[48] Another review concluded that there was "no compelling evidence" that any of these treatments were effective and that the available data on these products is particularly weak, with trials in this area suffering from many shortcomings, such as being small and poorly-designed and not testing for adverse effects.[49] One trial found that long term N-acetylcysteine (NAC) may decrease the severity of influenza symptoms.[50]

### Elderberry[edit | edit source]

Elderberry(Sambucus nigra)

Elderberry (Sambucus nigra) extract has been used by some in influenza.[51] The preparation has been reported to reduce the duration of influenza symptoms by raising levels of cytokines.[52]

However, use has been described as "imprudent" when an influenza strain causes death in healthy adults by cytokine storm leading to primary viral pneumonia.[53] The manufacturer cites a lack of evidence for cytokine-related risks, but labels the product only as an antioxidant and food supplement.[54]

### Green tea[edit | edit source]

High dietary intake of green tea (specifically, catechins and theanine that is found in tea products) has been correlated with reduced risk of influenza, as well as having an antiviral effect upon types A and B.[55][56][57]

## References[edit | edit source]

1. ↑ 1.0 1.1 1.2 Skalickova, Sylvie; Heger, Zbynek; Krejcova, Ludmila; Pekarik, Vladimir; Bastl, Karel; Janda, Jozef; Kostolansky, Frantisek; Vareckova, Eva; Zitka, Ondrej; Adam, Vojtech; Kizek, Rene (20 October 2015). "Perspective of Use of Antiviral Peptides against Influenza Virus". Viruses. 7 (10): 5428–5442. doi:10.3390/v7102883. ISSN 1999-4915. PMC 4632391. PMID 26492266.
2. ↑ Montalto NJ, Gum KD, Ashley JV (December 2000). "Updated treatment for influenza A and B". Am Fam Physician. 62 (11): 2467–76. PMID 11130232. Archived from the original on 2011-06-06. Retrieved 2009-04-29.
3. ↑ Research, Center for Drug Evaluation and (8 December 2022). "Influenza (Flu) Antiviral Drugs and Related Information". FDA. Archived from the original on 9 January 2020. Retrieved 10 October 2023.
4. ↑ "Influenza Antiviral Medications: Clinician Summary". Centers for Disease Control and Prevention. 27 September 2023. Archived from the original on 13 December 2014. Retrieved 10 October 2023.
5. ↑ Li, Guangdi; Jing, Xixi; Zhang, Pan; De Clercq, Erik (2021). "Antiviral Classification". Encyclopedia of Virology: 121–130. doi:10.1016/B978-0-12-814515-9.00126-0. Archived from the original on 20 October 2023. Retrieved 12 October 2023.
6. ↑ 6.0 6.1 "Taking Care of Yourself: What to Do if You Get Sick with Flu". Disease and Conditions: Seasonal Flu. CDC. 2008-02-06. Archived from the original on 2019-01-04. Retrieved 2008-10-24.
7. ↑ Ghebrehewet, Sam; MacPherson, Peter; Ho, Antonia (7 December 2016). "Influenza". BMJ (Clinical research ed.). 355: i6258. doi:10.1136/bmj.i6258. ISSN 1756-1833. Archived from the original on 4 April 2023. Retrieved 13 October 2023.
8. ↑ Boktor, Sameh W.; Hafner, John W. (2023). "Influenza". StatPearls. StatPearls Publishing. Archived from the original on 26 April 2023. Retrieved 12 October 2023.
9. ↑ "Flu Symptoms & Complications". Centers for Disease Control and Prevention. 3 October 2022. Archived from the original on 1 August 2020. Retrieved 14 October 2023.
10. ↑ "Cold and Flu Guidelines: Influenza". American Lung Association. Archived from the original on April 1, 2007. Retrieved 2007-09-16.
11. ↑ Molotsky I (1986-02-15). "Consumer Saturday – Warning on Flu and Aspirin". The New York Times. Archived from the original on 2020-04-03. Retrieved 2023-08-18.
12. ↑ Stiver, Grant (2003). "The treatment of influenza with antiviral drugs". Canadian Medical Association Journal. 168 (1): 49–57. PMC 139319. PMID 12515786 - via Pub Med.
13. ↑ Leekha, Surbhi; Terrell, Christine L.; Edson, Randall S. (2011). "General Principles of Antimicrobial Therapy". Mayo Clinic Proceedings. 86 (2): 156–167. doi:10.4065/mcp.2010.0639. ISSN 0025-6196. Archived from the original on 24 August 2023. Retrieved 12 October 2023.
14. ↑ 14.0 14.1 14.2 Centers for Disease Control and Prevention (3 September 2020). "What You Should Know about Flu Antiviral Drugs". Centers for Disease Control and Prevention (CDC). Archived from the original on 22 November 2020. Retrieved 26 November 2020.
15. ↑ Leneva, IA; Fediakina, IT; Gus'kova, TA; Glushkov, RG (2005). "[Sensitivity of various influenza virus strains to arbidol. Influence of arbidol combination with different antiviral drugs on reproduction of influenza virus A]". Терапевтический Архив (Therapeutic Archive). Moscow, Russia: ИЗДАТЕЛЬСТВО "МЕДИЦИНА". 77 (8): 84–88. PMID 16206613. Archived from the original on 2008-09-28. Retrieved 2008-10-24.
16. ↑ Shi L, Xiong H, He J, et al. (2007). "Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo". Arch. Virol. 152 (8): 1447–55. doi:10.1007/s00705-007-0974-5. PMID 17497238. S2CID 13595688.
17. ↑ V.D. Solov'ev (1969). "The results of controlled observations on the prophylaxis of influenza with interferon" (PDF). Bulletin of the World Health Organization. 41 (3): 683–688. PMC 2427762. PMID 5309493. Archived from the original (PDF) on June 4, 2011.
18. ↑ Joseph M. Cummins, DVM, Chad G. Thompson, BA (December 2004). "Low Dose Interferon, Immune Modulation and Emergency Influenza Prophylaxis". Pathobiologics International. Archived from the original on 2018-02-05. Retrieved 2023-08-18.`{{cite web}}`: CS1 maint: multiple names: authors list (link) – see also Cummins, Joseph M.; Krakowka, G. Steven; Thompson, Chad G. (January 2005). "Systemic effects of interferons after oral administration in animals and humans" (PDF). American Journal of Veterinary Research. 66 (1): 164–176. doi:10.2460/ajvr.2005.66.164. PMID 15691053. Archived from the original on 2020-04-06. Retrieved 2023-08-18.
19. ↑ "Amarillo Biosciences Selects Accelovance for Its Next Influenza Study". MarketWire. 2009-05-20. Archived from the original on 2020-04-03. Retrieved 2009-06-15.
20. ↑ Bracci L, Canini I, Venditti M, et al. (April 2006). "Type I IFN as a vaccine adjuvant for both systemic and mucosal vaccination against influenza virus". Vaccine. 24 (Suppl 2): S56–7. doi:10.1016/j.vaccine.2005.01.121. PMID 16823927.
21. ↑ Launay O, Grabar S, Bloch F, et al. (July 2008). "Effect of sublingual administration of interferon-alpha on the immune response to influenza vaccination in institutionalized elderly individuals". Vaccine. 26 (32): 4073–9. doi:10.1016/j.vaccine.2008.05.035. PMID 18602725.
22. ↑ "Russia through the prism of the world biopharmaceutical market" (PDF). Archived from the original (PDF) on 2012-02-24. Retrieved 2009-06-14.
23. ↑ Gatich RZ, Kolobukhina LV, Vasil'ev AN, Isaeva EI, Burtseva EI, Orlova TG, Voronina FV, Kol'tsov VD, Malinovskaia VV (2008). "Viferon suppositories in the treatment of influenza in adults (article in Russian)". Antibiot Khimioter. 53 (3–4): 13–7. PMID 18942420.
24. ↑ Kolobukhina LV, Malinovskaia VV, Gatich RZ, et al. (2008). "[Evaluation of the efficacy of wiferon and arbidol in adult influenza]". Vopr. Virusol. 53 (1): 31–3. PMID 18318133.
25. ↑ "Clinical Investigations of Grippferon". Archived from the original on 2011-07-06. Retrieved 2009-07-04.
26. ↑ "OPEN LETTER to: Director-General's office of the World Health Organization". February 2006. Archived from the original on 2011-07-06. Retrieved 2009-06-15.
27. ↑ Venkataramanan Soundararajan; Kannan Tharakaraman; Rahul Raman; S. Raguram; Zachary Shriver; V. Sasisekharan; Ram Sasisekharan (9 June 2009). "Extrapolating from sequence — the 2009 H1N1 'swine' influenza virus". Nature Biotechnology. 27 (6): 510–3. doi:10.1038/nbt0609-510. PMID 19513050. S2CID 22710439.
28. ↑ Lynch JP, Walsh EE (April 2007). "Influenza: evolving strategies in treatment and prevention". Semin Respir Crit Care Med. 28 (2): 144–58. doi:10.1055/s-2007-976487. PMID 17458769. S2CID 260316848.
29. ↑ Bright RA, Medina MJ, Xu X, et al. (October 2005). "Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern". Lancet. 366 (9492): 1175–81. doi:10.1016/S0140-6736(05)67338-2. PMID 16198766. S2CID 7386999.
30. ↑ Ilyushina NA, Govorkova EA, Webster RG (October 2005). "Detection of amantadine-resistant variants among avian influenza viruses isolated in North America and Asia". Virology. 341 (1): 102–6. doi:10.1016/j.virol.2005.07.003. PMID 16081121.
31. ↑ Parry J (July 2005). "Use of antiviral drug in poultry is blamed for drug resistant strains of avian flu". BMJ. 331 (7507): 10. doi:10.1136/bmj.331.7507.10. PMC 558527. PMID 15994677.
32. ↑ 32.0 32.1 Lackenby A, Thompson CI, Democratis J (December 2008). "The potential impact of neuraminidase inhibitor resistant influenza". Curr. Opin. Infect. Dis. 21 (6): 626–38. doi:10.1097/QCO.0b013e3283199797. PMID 18978531. S2CID 26989985.
33. ↑ Smith NM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, Strikas RA (July 2006). "Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP)" (PDF). MMWR Recomm Rep. Centers for Disease Control and Prevention. 55 (RR-10): 1–42. PMID 16874296. Archived (PDF) from the original on 2011-06-29. Retrieved 2023-08-18.
34. ↑ Altman LK (2006-01-15). "This Season's Flu Virus Is Resistant to 2 Standard Drugs". The New York Times. Archived from the original on 2013-05-11. Retrieved 2023-08-18.
35. ↑ D.S. Fedson (September 2008). "Confronting an influenza pandemic with inexpensive generic agents: can it be done?". The Lancet Infectious Diseases. 8 (9): 571–6. doi:10.1016/S1473-3099(08)70070-7. PMC 7128266. PMID 18420459.
36. ↑ Fedson DS (July 2006). "Pandemic influenza: a potential role for statins in treatment and prophylaxis". Clin. Infect. Dis. 43 (2): 199–205. doi:10.1086/505116. PMC 7107836. PMID 16779747.
37. ↑ Fedson DS, Dunnill P (2007). "Commentary: From scarcity to abundance: pandemic vaccines and other agents for "have not" countries". J Public Health Policy. 28 (3): 322–40. doi:10.1057/palgrave.jphp.3200147. PMID 17717543. S2CID 8373109.
38. ↑ Agamennone, Mariangela; Fantacuzzi, Marialuigia; Vivenzio, Giovanni; Scala, Maria Carmina; Campiglia, Pietro; Superti, Fabiana; Sala, Marina (January 2022). "Antiviral Peptides as Anti-Influenza Agents". International Journal of Molecular Sciences. 23 (19): 11433. doi:10.3390/ijms231911433. ISSN 1422-0067. Archived from the original on 26 April 2023. Retrieved 11 October 2023.
39. ↑ Nyanguile, Origène (2019). "Peptide Antiviral Strategies as an Alternative to Treat Lower Respiratory Viral Infections". Frontiers in Immunology. 10. doi:10.3389/fimmu.2019.01366/full. ISSN 1664-3224. Archived from the original on 28 November 2022. Retrieved 11 October 2023.
40. ↑ Thomas C. Luke, MD, MTMH; Edward M. Kilbane, MD, MPH; Jeffrey L. Jackson, MD, MPH; and Stephen L. Hoffman, MD, DTMH (2006-10-17). "Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?". Annals of Internal Medicine. 145 (8): 599–609. doi:10.7326/0003-4819-145-8-200610170-00139. PMID 16940336. S2CID 2929898.`{{cite journal}}`: CS1 maint: multiple names: authors list (link)
41. ↑ Jeffrey R. Ryan (2008). Pandemic Influenza. CRC Press. ISBN 978-1-4200-6087-4.
42. ↑ Korhonen H, Marnila P, Gill HS (November 2000). "Bovine milk antibodies for health". Br. J. Nutr. 84 (Suppl 1): S135–46. doi:10.1017/s0007114500002361. PMID 11242458. S2CID 12874865.
43. ↑ Kalamasz D, Long SA, Taniguchi R, Buckner JH, Berenson RJ, Bonyhadi M (2004). "Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and Anti-CD28 antibodies". J. Immunother. 27 (5): 405–18. doi:10.1097/00002371-200409000-00010. PMID 15314550. S2CID 19278587.
44. ↑ Boon AC, Vos AP, Graus YM, Rimmelzwaan GF, Osterhaus AD (January 2002). "In vitro effect of bioactive compounds on influenza virus specific B- and T-cell responses". Scand. J. Immunol. 55 (1): 24–32. doi:10.1046/j.1365-3083.2002.01014.x. PMID 11841689. S2CID 43746920.
45. ↑ Katona P, Katona-Apte J (May 2008). "The interaction between nutrition and infection". Clin. Infect. Dis. 46 (10): 1582–8. doi:10.1086/587658. PMID 18419494.
46. ↑ Cannell JJ, Zasloff M, Garland CF, Scragg R, Giovannucci E (2008). "On the epidemiology of influenza". Virol. J. 5: 29. doi:10.1186/1743-422X-5-29. PMC 2279112. PMID 18298852.
47. ↑ Yamshchikov AV, Desai NS, Blumberg HM, Ziegler TR, Tangpricha V (2009). "Vitamin D for treatment and prevention of infectious diseases: a systematic review of randomized controlled trials". Endocr Pract. 15 (5): 438–49. doi:10.4158/EP09101.ORR. PMC 2855046. PMID 19491064.
48. ↑ Mario Roxas, ND and Julie Jurenka, MT (ASCP) (2007). "Colds and Influenza: A Review of Diagnosis and Conventional, Botanical, and Nutritional Considerations" (PDF). Alternative Medicine Review. 12 (1): 25–48. PMID 17397266. Archived from the original (PDF) on 2011-07-28. Retrieved 2009-06-13.`{{cite journal}}`: CS1 maint: multiple names: authors list (link)
49. ↑ Guo R, Pittler MH, Ernst E (November 2007). "Complementary medicine for treating or preventing influenza or influenza-like illness". Am. J. Med. 120 (11): 923–929.e3. doi:10.1016/j.amjmed.2007.06.031. PMID 17976414.
50. ↑ Millea, PJ (1 August 2009). "N-acetylcysteine: multiple clinical applications". American family physician. 80 (3): 265–9. PMID 19621836.
51. ↑ "Elderberry". Drugs and Lactation Database (LactMed®). National Institute of Child Health and Human Development. 2021. PMID 30000895. Archived from the original on 2021-04-16. Retrieved 2023-10-13.
52. ↑ Barak, V; Halperin, T; Kalickman, I (June 2001). "The effect of Sambucol, a black elderberry-based, natural product, on the production of human cytokines: I. Inflammatory cytokines". European Cytokine Network. 12 (2): 290–296. PMID 11399518. Archived from the original on 2009-05-07. Retrieved 2023-08-18.
53. ↑ Jeffrey R. Ryan (2008). Pandemic Influenza. CRC Press. ISBN 978-1-4200-6087-4.
54. ↑ "Sambucol FAQs". Manufacturer Web site. Archived from the original on 2009-07-25. Retrieved 2009-06-13.
55. ↑ Matsumoto, K; Yamada, H; Takuma, N; Niino, H; Sagesaka, YM (2005). "Effects of green tea catechins and theanine on preventing influenza infection among healthcare workers: a randomized controlled trial". BMC Complement Altern Med. 11: 15. doi:10.1186/1472-6882-11-15. PMC 3049752. PMID 21338496.
56. ↑ Park, M; Yamada, H; Matsushita, K; Kaji, S; Goto, T; Okada, Y; Kosuge, K; Kitagawa, T (2011). "Green tea consumption is inversely associated with the incidence of influenza infection among schoolchildren in a tea plantation area of Japan". J. Nutr. 141 (10): 1862–70. doi:10.3945/jn.110.137547. PMID 21832025.
57. ↑ Imanishi, N; Tuji, Y; Katada, Y; Maruhashi, M; Konosu, S; Mantani, N; Terasawa, K; Ochiai, H (2002). "Additional inhibitory effect of tea extract on the growth of influenza A and B viruses in MDCK cells". Microbiol. Immunol. 46 (7): 491–4. doi:10.1111/j.1348-0421.2002.tb02724.x. PMID 12222936. S2CID 24102910.

## Further reading[edit | edit source]

* American Academy of Pediatrics Committee on Infectious Diseases (April 2008). "Prevention of influenza: recommendations for influenza immunization of children, 2007–2008". Pediatrics. 121 (4): e1016–31. doi:10.1542/peds.2008-0160. PMID 18381500. S2CID 5352547.
* Andre FE, Booy R, Bock HL, et al. (February 2008). "Vaccination greatly reduces disease, disability, death and inequity worldwide". Bull. World Health Organ. 86 (2): 140–6. doi:10.2471/BLT.07.040089. PMC 2647387. PMID 18297169. Archived from the original on 2019-09-22. Retrieved 2023-08-18.
* Basta NE, Halloran ME, Matrajt L, Longini IM (December 2008). "Estimating influenza vaccine efficacy from challenge and community-based study data". Am. J. Epidemiol. 168 (12): 1343–52. doi:10.1093/aje/kwn259. PMC 2638553. PMID 18974084.`{{cite journal}}`: CS1 maint: multiple names: authors list (link)
* Beigel J, Bray M (April 2008). "Current and future antiviral therapy of severe seasonal and avian influenza". Antiviral Res. 78 (1): 91–102. doi:10.1016/j.antiviral.2008.01.003. PMC 2346583. PMID 18328578.
* Hampson AW (June 2008). "Vaccines for pandemic influenza. The history of our current vaccines, their limitations and the requirements to deal with a pandemic threat" (PDF). Ann. Acad. Med. Singap. 37 (6): 510–7. doi:10.47102/annals-acadmedsg.V37N6p510. PMID 18618064. S2CID 17102174. Archived (PDF) from the original on 2011-07-21. Retrieved 2023-08-18.
* Lipatov AS, Govorkova EA, Webby RJ, et al. (September 2004). "Influenza: emergence and control". J. Virol. 78 (17): 8951–9. doi:10.1128/JVI.78.17.8951-8959.2004. PMC 506949. PMID 15308692.
* Mossad SB (December 2008). "2008-2009 Influenza update: a better vaccine match". Cleve Clin J Med. 75 (12): 865–70. doi:10.3949/ccjm.75a.08088. PMID 19088005. S2CID 9036512.
* Mossad SB (December 2007). "Influenza update 2007-2008: vaccine advances, pandemic preparation". Cleve Clin J Med. 74 (12): 889–94. doi:10.3949/ccjm.74.12.889. PMID 18183839. S2CID 23819922. Archived from the original on 2023-08-26. Retrieved 2023-08-18.
* Nichols WG, Peck Campbell AJ, Boeckh M (April 2008). "Respiratory viruses other than influenza virus: impact and therapeutic advances". Clin. Microbiol. Rev. 21 (2): 274–90, table of contents. doi:10.1128/CMR.00045-07. PMC 2292575. PMID 18400797.
* Oshitani H, Kamigaki T, Suzuki A (June 2008). "Major issues and challenges of influenza pandemic preparedness in developing countries". Emerging Infect. Dis. 14 (6): 875–80. doi:10.3201/eid1406.070839. PMC 2600290. PMID 18507896.
* Sugrue RJ, Tan BH, Yeo DS, Sutejo R (June 2008). "Antiviral drugs for the control of pandemic influenza virus" (PDF). Ann. Acad. Med. Singap. 37 (6): 518–24. doi:10.47102/annals-acadmedsg.V37N6p518. PMID 18618065. S2CID 14606874. Archived (PDF) from the original on 2011-07-21. Retrieved 2023-08-18.
* Tosh PK, Boyce TG, Poland GA (January 2008). "Flu myths: dispelling the myths associated with live attenuated influenza vaccine". Mayo Clin. Proc. 83 (1): 77–84. doi:10.4065/83.1.77. PMID 18174020.
* von Itzstein M (December 2007). "The war against influenza: discovery and development of sialidase inhibitors". Nat Rev Drug Discov. 6 (12): 967–74. doi:10.1038/nrd2400. PMID 18049471. S2CID 36867756.
* Wu J, Yan P, Archibald C (2007). "Modelling the evolution of drug resistance in the presence of antiviral drugs". BMC Public Health. 7: 300. doi:10.1186/1471-2458-7-300. PMC 2148062. PMID 17953775.

## External links[edit | edit source]

* Health-EU Portal Archived 2013-09-22 at the Wayback Machine EU response to influenza.
* European Commission – Public Health Archived 2016-03-04 at the Wayback Machine EU coordination on Pandemic (H1N1) 2009
* Flu treatment Archived 2017-11-19 at the Wayback Machine WebMD recommendations
* Influenza Archived 2008-03-17 at the Wayback Machine Merck Manual, February 2007

* v
* t
* e

Influenza

General topics|

* Research
* Vaccine
* Treatment
* Genome sequencing
* Reassortment
* Superinfection
* Flu season

Viruses|

* Orthomyxoviridae
* Influenza A
* Influenza B
* Influenza C
* Influenza D

Influenza A virus
subtypes

* H1N1
* H1N2
* H2N2
* H2N3
* H3N1
* H3N2
* H3N8
* H5N1
* H5N2
* H5N3
* H5N6
* H5N8
* H5N9
* H6N1
* H7N1
* H7N2
* H7N3
* H7N4
* H7N7
* H7N9
* H9N2
* H10N7
* H10N8
* H11N2
* H11N9

H1N1|

| Pandemics|

* 1918 (Spanish flu)
* 2009 (Swine flu)

|

Science|

* 2009 A/H1N1

H5N1|

| Outbreaks|

* Croatia (2005)
* India (2006)
* UK (2007)
* West Bengal (2008)

|

Science|

* Genetic structure
* Transmission and infection
* Global spread
* Vaccine
* clinical trials
* Human mortality
* Social impact
* Pandemic preparation

Treatments|

| Antiviral drugs|

* Adamantane derivatives
* Amantadine
* Rimantadine
* Neuraminidase inhibitor
* Oseltamivir
* Laninamivir
* Peramivir
* Zanamivir
* Peramivir (experimental)
* Umifenovir
* Baloxavir marboxil

|

Vaccines|

* Live attenuated influenza vaccine
* Brands
* Pandemrix
* Audenz

Pandemics and
epidemics

| Pandemics|

* Influenza pandemic (1510)
* Influenza pandemic (1557)
* "Russian flu" (1889-1890)
* "Spanish flu" (1918)
* "Asian flu" (1957)
* "Hong Kong flu" (1968)
* "Swine flu" (2009)

|

Epidemics|

* "Russian flu" (1977-1978)
* "Fujian flu" (H3N2)
* 1989–90 UK outbreak
* Central Luzon H5N6 (2017)

Non-human|

| Mammals|

* Canine
* Feline
* Equine
* 2007 Australian outbreak
* Swine

|

Non-mammals|

* Avian
* Fujian (H5N1)

Complications|

* Acute bronchitis
* Bronchiolitis
* Croup
* Otitis media
* Pharyngitis
* Pneumonia
* Sinusitis
* Strep throat

Related topics|

* Influenza-like illness
* 2017–2018 United States flu season
* US influenza statistics by flu season

*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template